Pain in chronic kidney disease: A scoping review

Seminars in Dialysis

Volumn 27, Issue 2, 2014, Pages 188-204

  Davison, Sara N ^a   Koncicki, Holly ^b   Brennan, Frank ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT;

ANALGESIA; CHRONIC KIDNEY FAILURE; COMPLICATION; HUMAN; KIDNEY POLYCYSTIC DISEASE; MEDICAL RESEARCH; PAIN; PROCEDURES;

ANALGESICS; BIOMEDICAL RESEARCH; HUMANS; PAIN; PAIN MANAGEMENT; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL INSUFFICIENCY, CHRONIC;

EID: 84895114835     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12196     Document Type: Article

References (181)

1. Arksey H, O'Malley L: Scoping studies: Towards a methodological framework. Int J Soc Res Methodol 8:19-32, 2005
2. Murtagh FE, Addington-Hall JM, Edmonds PM, Donohoe P, Carey I, Jenkins K, Higginson IJ: Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J Palliat Med 10:1266-1276, 2007
3. Murphy EL, Murtagh FE, Carey I, Sheerin NS: Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool. Nephron Clin Pract 111:c74-c80, 2009
4. Noble H, Meyer PJ, Bridge DJ, Johnson DB, Kelly DD: Exploring symptoms in patients managed without dialysis: a qualitative research study. J Ren Care 36:9-15, 2010
5. Davison SN: Chronic pain in end-stage renal disease. Adv Chronic Kidney Dis 12:326-334, 2005
6. Davison SN, Jhangri GS: Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manage 39:477-485, 2010
7. Davison SN, Jhangri GS, Johnson JA: Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int 69:1621-1625, 2006
8. Davison SN, Jhangri GS, Johnson JA: Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrol Dial Transplant 21:3189-3195, 2006
9. Kimmel PL, Emont SL, Newmann JM, Danko H, Moss AH: ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis 42:713-721, 2003
10. Leinau L, Murphy TE, Bradley E, Fried T: Relationship between conditions addressed by hemodialysis guidelines and non-ESRD-specific conditions affecting quality of life. Clin J Am Soc Nephrol 4:572-578, 2009
11. Weisbord SD, Carmody SS, Bruns FJ, Rotondi AJ, Cohen LM, Zeidel ML, Arnold RM: Symptom burden, quality of life, advance care planning and the potential value of palliative care in severely ill haemodialysis patients. Nephrol Dial Transplant 18:1345-1352, 2003
12. Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA, Switzer GE: Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 16:2487-2494, 2005
13. Gamondi C, Galli N, Schonholzer C, Marone C, Zwahlen H, Gabutti L, Bianchi G, Ferrier C, Cereghetti C, Giannini O: Frequency and severity of pain and symptom distress among patients with chronic kidney disease receiving dialysis. Swiss Med Wkly 143:w13750, 2013
14. Bailie GR, Mason NA, Bragg-Gresham JL, Gillespie BW, Young EW: Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for under prescription. Kidney Int 65:2419-2425, 2004
15. Elder SJ, Pisoni RL, Akizawa T, Fissell R, Andreucci VE, Fukuhara S, Kurokawa K, Rayner HC, Furniss AL, Port FK, Saran R: Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol DialTransplant 23:998-1004, 2008
16. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358-1366, 2006
17. Plantinga L, Grubbs V, Sarkar U, Hsu CY, Hedgeman E, Robinson B, Saran R, Geiss L, Burrows NR, Eberhardt M, Powe N, CDC CKD ST: Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med 9:423-430, 2011
18. US Renal Data System: USRDS Dialysis Morbidity and Mortality Study. USRDS: Annual Data Report. Bethesda, MD: NIH, NIDDK, 1998
19. Desmet C, Beguin C, Swine C, Jadoul M: Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. Am J Kidney Dis 45:148-153, 2005
20. Shah HH, Monga D, Caperna A, Jhaveri KD: Palliative care experience of US adult nephrology fellows: a national survey. Ren Fail 36:39-45, 2014
21. Weisbord SD, Fried LF, Mor MK, Resnick AL, Unruh ML, Palevsky PM, Levenson DJ, Cooksey SH, Fine MJ, Kimmel PL, Arnold RM: Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2:960-967, 2007
22. Walke LM, Byers AL, McCorkle R, Fried TR: Symptom assessment in community-dwelling older adults with advanced chronic disease. J Pain Symptom Manage 31:31-37, 2006
23. Hearn J, Higginson IJ: Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual Health Care 8:219-227, 1999
24. Barakzoy AS, Moss AH: Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol 17:3198-3203, 2006
25. Broadbent A, Khor K, Heaney A: Palliation and renal failure: Common non-opioid medication guidelines. Prog Palliat Care 5:9-64, 2003
26. Davison SN, Ferro CJ: Management of pain in chronic kidney disease. Prog Palliat Care 18:6-195, 2009
27. Davison SN, Chambers EJ, Ferro CJ: Management of pain in renal failure. In: Chambers EJ, Brown E, Germain M (eds). Supportive Care for the Renal Patient, 2nd edn. New York: Oxford University Press, 2010:139-188
28. Davison SN: Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis 42:1239-1247, 2003
29. Davison SN: The prevalence and management of chronic pain in end-stage renal disease. J Palliat Med 127:7-1287, 2007
30. Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage 28:497-504, 2004
31. Harris D: Pain management in patients with renal impairment. Eur J Palliat Care 15:214-216, 2008
32. Kurella M, Bennett WM, Chertow GM: Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 42:217-228, 2003
33. Launay-Vacher V, Karie S, Fau J-B, Izzedine H, Deray G: Treatment of pain in patients with renal insufficiency: The World Health Organization three-step ladder adapted. J Pain 6:137-148, 2005
34. Mid-Atlantic Renal Coalition and the Kidney End-of-Life Coalition. Clinical algorithm & preferred medications to treat pain in dialysis patients, Richmond, VA: Mid-Atlantic Renal Coalition and the Kidney End-of-Life Coalition, 2009
35. Moss AH: Pain Management in ESKD. Presentation from Kidney End-of-Life Coalition (USDA).
36. Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ: Symptom management in patients with established renal failure managed without dialysis. Edtna Erca J 32:93-98, 2006
37. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ: The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 21:5-16, 2007
38. Naylor HK, Raymond CB: Treatment of neuropathic pain in patients with chronic kidney disease. CANNT J 21:34-38, 2011
39. Young BA, Hynes J, McComb T, Blagg CR: Associations with home hemodialysis modality failure and mortality. Hemodial Int 8:344-348, 2004
40. Niscola P, Scaramucci L, Vischini G, Giovannini M, Ferrannini M, Massa P, Tatangelo P, Galletti M, Palumbo R: The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 11:752-758, 2010
41. Pham PC, Toscano E, Pham PM, Pham PA, Pham SV, Pham PT: Pain management in patients with chronic kidney disease. NDT Plus 2:111-118, 2009
42. Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SM; APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine (2010): Acute Pain Management: Scientific Evidence (3rd edn). ANZCA & FPM: Melbourne
43. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10:113-130, 2009
44. Horber FF, Guentert TW, Weidekamm E, Heizmann P, Descoeudres C, Frey FJ: Pharmacokinetics of tenoxicam in patients with impaired renal function. Eur J Clin Pharmacol 29:697-701, 1986
45. Daousi C, Nurmikko T: Painful diabetic neuropathy. In: Stannard C, Kalso E, Ballantyne J (eds). Evidence - Based Chronic Pain Management, West Sussex: BMJ Books, 2010:204-221
46. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD: Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85:S3-S14, 2010
47. Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A: Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician 57: 1269-1276, e1419-1228, 2011
48. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, Patel S, Manchikanti L: Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain physician 11:S5-S62, 2008
49. Ferrell B, Argoff CE, Epplin J, Fine P, Gloth FM, Herr K, Katz JD, Mehr DR, Reid C, Reisner L. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57: 1331-1346, 2009
50. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P: Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287-313, 2008
51. Bajwa ZH, Gupta S, Warfield CA, Steinman TI: Pain management in polycystic kidney disease. Kidney Int 60:1631-1644, 2001
52. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ: Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 34:2220-2224, 2011
53. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ: Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 21:976-982, 2004
54. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS: Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 8(Suppl 2):S50-S62, 2007
55. Innis J: Pain assessment and management for a dialysis patient with diabetic peripheral neuropathy. CANNT J 16:12-17, 2006
56. Eggers PW, Gohdes D, Pugh J: Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 56:1524-1533, 1999
57. Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, Mathieu C, Colin IM: Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 35:206-213, 2009
58. Jensen MP, Chodroff MJ, Dworkin RH: The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 68:1178-1182, 2007
59. Zelman DC, Brandenburg NA, Gore M: Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 22:681-685, 2006
60. Vileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS, Garrow A, Waterman C, Cavanagh PR, Boulton AJ: Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care 28:2378-2383, 2005
61. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B: Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 30:374-385, 2005
62. Moghtaderi A, Bakhshipour A, Rashidi H: Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg 108:477-481, 2006
63. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lanteri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114:29-36, 2005
64. Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, Vinik A, Boulton A: Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 27:629-638, 2011
65. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D: Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 76:1758-1765, 2011
66. Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark MR, Cole BE, Fishbain DA, Irving GA, McCarberg BH, McLean MJ: Consensus guidelines: treatment planning and options. Mayo Clin Proc 81:S12-S25, 2006
67. Pop-Busui R, Roberts L, Pennathur S, Kretzler M, Brosius FC, Feldman EL: The management of diabetic neuropathy in CKD. Am J Kidney Dis 55:365-385, 2010
68. Diabetes Control Complications Trial (DCCT) Research Group: Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 38: 869-880, 1995
69. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
70. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139, 2009
71. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831-1836, 1998
72. Freeman R, Durso-Decruz E, Emir B: Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 31:1448-1454, 2008
73. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H: Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 19:3137-3139, 2004
74. Micozkadioglu H, Ozdemir FN, Kut A, Sezer S, Saatci U, Haberal M: Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: An open-label study. Ren Fail 26:393-397, 2004
75. Thorp ML, Morris CD, Bagby SP: A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 38:104-108, 2001
76. Biyik Z, Solak Y, Atalay H, Gaipov A, Guney F, Turk S: Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. Int Urol Nephrol 45:831-837, 2013
77. Lo HS, Yang CM, Lo HG, Lee CY, Ting H, Tzang BS: Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol 33:84-90, 2010
78. Barisic I, Ljutic D, Jankovic S, Vlak T, Tomic S, Kokic S, Erceg M: Relevant sonographic parameters of a painful shoulder in symptomatic dialyzed patients versus asymptomatic dialyzed and healthy volunteers. Coll Antropol 30:313-318, 2006
79. Hardouin P, Flipo RM, Foissac-Gegoux P, Dumont A, Duquesnoy B, Delcambre B: Dialysis-related beta 2 microglobulin-amyloid arthropathy. Improvement of clinical symptoms after a switch of dialysis membranes. Clin Rheumatol 7:41-45, 1988
80. Bernageau J, Bardin T, Goutallier D, Voisin MC, Bard M: Magnetic resonance imaging findings in shoulders of hemodialyzed patients. Clin Orthop Relat Res 9:1-96, 1994
81. Dervisoglu E, Anik Y, Erdogan S, Akansel G, Yilmaz A: Beta2-microglobulin amyloidosis in hemodialysis and peritoneal dialysis patients. Ther Apher Dialysis 12:306-310, 2008
82. Charra B, Calemard E, Uzan M, Terrat JC, Vanel T, Laurent G: Carpal tunnel syndrome, shoulder pain and amyloid deposits in long-term haemodialysis patients. Proc Eur Dial Transplant Assoc Eur Ren Assoc 21:291-295, 1985
83. Marks JL, van dH, Colebatch AN, Buchbinder R, Edwards CJ: Pain pharmacotherapy in patients with inflammatory arthritis and concurrent cardiovascular or renal disease: a Cochrane systematic review. J Rheumatol 90:81-84, 2012
84. Coleman SH, Madsen M, Di Carlo EF, Sullivan JF, Wickiewicz TL: Arthroscopic synovectomy for the management of shoulder arthropathy in chronic renal dialysis patients. J Shoulder Elbow Surg 12:144-147, 2003
85. Cofan F, Garcia S, Combalia A, Segur JM, Oppenheimer F: Carpal tunnel syndrome secondary to uraemic tumoral calcinosis. Rheumatology 41:701-703, 2002
86. Harding AE, Le Fanu J: Carpal tunnel syndrome related to antebrachial Cimino-Brescia fistula. J Neurol Neurosurg Psychiatry 40:511-513, 1977
87. Kumar S, Trivedi HL, Smith EK: Carpal tunnel syndrome: a complication of arteriovenous fistula in hemodialysis patients. Can Med Assoc J 113:1070-1072, 1975
88. Gilbert MS, Robinson A, Baez A, Gupta S, Glabman S, Haimov M: Carpal tunnel syndrome in patients who are receiving long-term renal hemodialysis. J Bone Joint Surg Am 70:1145-1153, 1988
89. Bicknell JM, Lim AC, Raroque HG Jr, Tzamaloukas AH: Carpal tunnel syndrome, subclinical median mononeuropathy, and peripheral polyneuropathy: common early complications of chronic peritoneal dialysis and hemodialysis. Arch Phys Med Rehabil 72:378-381, 1991
90. Asencio G, Rigout C, Ramperez P, Branger B, Oules R, Bertin R, Megy B, Leonardi C: Hemodialysis-related lesions of the hand. Rev Rhum Engl Ed 62:233-240, 1995
91. Sivri A, Celiker R, Sungur C, Kutsal YG: Carpal tunnel syndrome: a major complication in hemodialysis patients. Scand J Rheumatol 23:287-290, 1994
92. Warren DJ, Otieno LS: Carpal tunnel syndrome in patients on intermittent haemodialysis. Postgrad Med J 51:450-452, 1975
93. Kessler M, Netter P, Azoulay E, Mayeux D, Pere P, Gaucher A: Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 31:157-162, 1992
94. Harris SA, Brown EA: Patients surviving more than 10 years on haemodialysis. The natural history of the complications of treatment. Nephrol Dial Transplant 13:1226-1233, 1998
95. Ikegaya N, Hishida A, Sawada K, Furuhashi M, Maruyama Y, Kumagai H, Kobayashi S, Yamamoto T, Yamazaki K: Ultrasonographic evaluation of the carpal tunnel syndrome in hemodialysis patients. Clin Nephrol 44:231-237, 1995
96. Otsubo S, Kimata N, Okutsu I, Oshikawa K, Ueda S, Sugimoto H, Mitobe M, Uchida K, Otsubo K, Nitta K, Akiba T: Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 24:1593-1598, 2009
97. Kwon HK, Pyun SB, Cho WY, Boo CS: Carpal tunnel syndrome and peripheral polyneuropathy in patients with end stage kidney disease. J Korean Med Sci 26:1227-1230, 2011
98. Levine DW, Simmons BP, Koris MJ, Daltroy LH, Hohl GG, Fossel AH, Katz JN: A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. J Bone Joint Surg Am 75:1585-1592, 1993
99. Shiota E, Tsuchiya K, Yamaoka K, Kawano O: Open carpal tunnel decompression in long-term haemodialysis patients. J Hand Surg 26:529-532, 2001
100. Hirasawa Y, Ogura T: Carpal tunnel syndrome in patients on long-term haemodialysis. Scand J Plast Reconstr Surg Hand Surg 34:373-381, 2000
101. Kim SJ, Shin SJ, Kang ES: Endoscopic carpal tunnel release in patients receiving long-term hemodialysis. Clin Orthop Relat Res 14:1-148, 2000
102. Yoshida A, Okutsu I, Hamanaka I, Motomura T: Results of endoscopic management of primary versus recurrent carpal tunnel syndrome in long-term haemodialysis patients. Hand Surg 9:165-170, 2004
103. Spencer JD: Amyloidosis as a cause of carpal tunnel syndrome in haemodialysis patients. J Hand Surg 13:402-405, 1988
104. Badani KK, Hemal AK, Menon M: Autosomal dominant polycystic kidney disease and pain - a review of the disease from aetiology, evaluation, past surgical treatment options to current practice. J Postgrad Med 50:222-226, 2004
105. Grantham JJ: Renal pain in polycystic kidney disease: when the hurt won't stop. J Am Soc Nephrol 2:1161-1162, 1992
106. Hogan MC, Norby SM: Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17:e1-e16, 2010
107. Bajwa ZH, Sial KA, Malik AB, Steinman TI: Pain patterns in patients with polycystic kidney disease. Kidney Int 66:1561-1569, 2004
108. Kim SH, Moon MW, Lee HJ, Sim JS, Kim SH, Ahn C: Renal cyst ablation with n-butyl cyanoacrylate and iodized oil in symptomatic patients with autosomal dominant polycystic kidney disease: preliminary report. Radiology 226:573-576, 2003
109. Uemasu J, Fujihara M, Munemura C, Nakamura E, Kawasaki H: Cyst sclerotherapy with minocycline hydrochloride in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 11:843-846, 1996
110. Singh I, Mehrotra G: Selective ablation of symptomatic dominant renal cysts using 99% ethanol in adult polycystic kidney disease. Urology 68:482-487, 2006
111. Lee YR, Lee KB: Ablation of symptomatic cysts using absolute ethanol in 11 patients with autosomal-dominant polycystic kidney disease. Korean J Radiol 4:239-242, 2003
112. Chehval MJ, Neilsen C: Laparoscopic cyst decompression in polycystic kidney disease. J Endourol 9:281-282, 1995
113. Hemal AK, Gupta NP, Rajeev TP, Aron M, Bhowmik D, Jain R: Retroperitoneoscopic management of infected cysts in adult polycystic kidney disease. Urol Int 62:40-43, 1999
114. Sulikowski T, Kaminski M, Rozanski J, Zietek Z, Domanski L, Majewski W, Sienko J, Romanowski M, Mizerski A, Myslak M, Tejchman K, Pabisiak K, Nowacki M, Ostrowski M, Ciechanowski K: Laparoscopic removal of renal cysts in patients with ADPKD as an alternative method of treatment and patient preparation for kidney transplantation: preliminary results. Transpl Proc 38:23-27, 2006
115. Brown JA, Torres VE, King BF, Segura JW: Laparoscopic marsupialization of symptomatic polycystic kidney disease. J Urol 156:22-27, 1996
116. McNally ML, Erturk E, Oleyourryk G, Schoeniger L: Laparoscopic cyst decortication using the harmonic scalpel for symptomatic autosomal dominant polycystic kidney disease. J Endourol 15:597-599, 2001
117. Elashry OM, Nakada SY, Wolf JS Jr, McDougall EM, Clayman RV: Laparoscopy for adult polycystic kidney disease: a promising alternative. Am J Kidney Dis 27:224-233, 1996
118. Teichman JM, Hulbert JC: Laparoscopic marsupialization of the painful polycystic kidney. J Urol 153:1105-1107, 1995
119. Elzinga LW, Barry JM, Torres VE, Zincke H, Wahner HW, Swan S, Bennett WM: Cyst decompression surgery for autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2:1219-1226, 1992
120. Lee DI, Andreoni CR, Rehman J, Landman J, Ragab M, Yan Y, Chen C, Shindel A, Middleton W, Shalhav A, McDougall EM, Clayman RV: Laparoscopic cyst decortication in autosomal dominant polycystic kidney disease: impact on pain, hypertension, and renal function. J Endourol 17:345-354, 2003
121. Haseebuddin M, Tanagho YS, Millar M, Roytman T, Chen C, Clayman RV, Miller B, Desai A, Benway B, Bhayani S, Figenshau RS: Long-term impact of laparoscopic cyst decortication on renal function, hypertension and pain control in patients with autosomal dominant polycystic kidney disease. J Urol 188:1239-1244, 2012
122. Gill IS, Kaouk JH, Hobart MG, Sung GT, Schweizer DK, Braun WE: Laparoscopic bilateral synchronous nephrectomy for autosomal dominant polycystic kidney disease: The initial experience. J Urol 165:1093-1098, 2001
123. Lipke MC, Bargman V, Milgrom M, Sundaram CP: Limitations of laparoscopy for bilateral nephrectomy for autosomal dominant polycystic kidney disease. J Urol 177:627-631, 2007
124. Dunn MD, Portis AJ, Elbahnasy AM, Shalhav AL, Rothstein M, McDougall EM, Clayman RV: Laparoscopic nephrectomy in patients with end-stage renal disease and autosomal dominant polycystic kidney disease. Am J Kidney Dis 35:720-725, 2000
125. Jenkins MA, Crane JJ, Munch LC: Bilateral hand-assisted laparoscopic nephrectomy for autosomal dominant polycystic kidney disease using a single midline HandPort incision. Urology 59:32-36, 2002
126. Rehman J, Landman J, Andreoni C, McDougall EM, Clayman RV: Laparoscopic bilateral hand assisted nephrectomy for autosomal dominant polycystic kidney disease: initial experience. J Urol 166:42-47, 2001
127. Valente JF, Dreyer DR, Breda MA, Bennett WM: Laparoscopic renal denervation for intractable ADPKD-related pain. Nephrol Dial Transplant 16:160, 2001
128. Casale P, Meyers K, Kaplan B: Follow-up for laparoscopic renal denervation and nephropexy for autosomal dominant polycystic kidney disease-related pain in pediatrics. J Endourol 22:991-993, 2008
129. Chiou CP: Development and psychometric assessment of the physical symptom distress scale. J Pain Symptom Manage 16:87-95, 1998
130. Weisbord SD, Fried LF, Arnold RM, Rotondi AJ, Fine MJ, Levenson DJ, Switzer GE: Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J Pain Symptom Manage 27:226-240, 2004
131. Melzack R: The McGill Pain Questionnaire: major properties and scoring methods. Pain 1:277-299, 1975
132. Joshi VD, Mooppil N, Lim JF: Validation of the kidney disease quality of life-short form: a cross-sectional study of a dialysis-targeted health measure in Singapore. BMC Nephrol 11:36, 2010
133. Wu AW, Fink NE, Cagney KA, Bass EB, Rubin HR, Meyer KB, Sadler JH, Powe NR: Developing a health-related quality-of-life measure for end-stage renal disease: the CHOICE Health Experience Questionnaire. Am J Kidney Dis 37:11-21, 2001
134. Prescott LF: Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs 23:75-149, 1982
135. Prescott LF, Speirs GC, Critchley JA, Temple RM, Winney RJ: Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 36:291-297, 1989
136. Ashley C, Currie AE: The Renal Drug Handbook. Oxford: Radcliffe Publishing, 2009
137. Way EL, Adler TK: The pharmacologic implications of the fate of morphine and its surrogates. Pharmacol Rev 12:383-446, 1960
138. Guay DR, Awni WM, Findlay JW, Halstenson CE, Abraham PA, Opsahl JA, Jones EC, Matzke GR: Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 43:63-71, 1988
139. Schug SA, Morgan J: Treatment of cancer pain: Special considerations in patients with renal disease. Am J Cancer 3:247-256, 2004
140. Izzedine H, Launay-Vacher V, Abbara C, Aymard G, Bassilios N, Deray G: Pharmacokinetics of tramadol in a hemodialysis patient. Nephron 92:755-756, 2002
141. Gibson TP: Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Am J Med 101:47S-53S, 1996
142. Paramanandam G, Prommer E, Schwenke DC: Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. J Palliat Med 14:1029-1033, 2011
143. Davison SN, Mayo PR: Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag 4:335-336, 2008
144. Davies G, Kingswood C, Street M: Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 31:410-422, 1996
145. Chauvin M, Lebrault C, Levron JC, Duvaldestin P: Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 66:53-56, 1987
146. Filitz J, Griessinger N, Sittl R, Likar R, Schuttler J, Koppert W: Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 10:743-748, 2006
147. Mordarski S: Efficacy and safety of buprenorphine in patients receiving haemodialysis. J Appl Res 7:46-51, 2009
148. Berg KJ, Talseth T: Acute renal effects of sulindac and indomethacin in chronic renal failure. Clin Pharmacol Ther 37:447-452, 1985
149. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M: Methadone use in patients with chronic renal disease. Drug Alcohol Depend 5:197-205, 1980
150. Fitzgerald J: Narcotic analgesics in renal failure. Conn Med 55:701-704, 1991
151. Foral PA, Ineck JR, Nystrom KK: Oxycodone accumulation in a hemodialysis patient. South Med J 100:212-214, 2007
152. Kirvela M, Lindgren L, Seppala T, Olkkola KT: The Pharmacokinetics of Oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 8:13-18, 1996
153. Kaiko R, Benziger D, Cheng C, Hou Y, Grandy R: Clinical Pharmacokinetics of Controlled-Release Oxycodone in Renal Impairment. Clin Pharmacol Ther 59:130-130, 1996
154. Inturrisi CE, Verebely K: Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 13:923-930, 1972
155. Wong MO, Eldon MA, Keane WF, Turck D, Bockbrader HN, Underwood BA, Sedman AJ, Halstenson CE: Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 35:622-626, 1995
156. Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch JA, Reece PA, Sedman AJ: Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 56:154-159, 1994
157. MIMS: MIMS Annual. St. Leonards, NSW: UBM Medica Australia, 2010
158. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN: Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 43:277-283, 2003
159. Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R, Kane JM: Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 37:301-307, 1985
160. Sandoz M, Vandel S, Vandel B, Bonin B, Hory B, St HY, Volmat R: Metabolism of amitriptyline in patients with chronic renal failure. Eur J Clin Pharmacol 26:227-232, 1984
161. Ciabattoni G, Cinotti GA, Pierucci A, Simonetti BM, Manzi M, Pugliese F, Barsotti P, Pecci G, Taggi F, Patrono C: Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. N Engl J Med 310:279-283, 1984
162. Bunning RD, Barth WF: Sulindac. A potentially renal-sparing nonsteroidal anti-inflammatory drug. JAMA 248:2864-2867, 1982
163. Swainson CP, Griffiths P: Acute and chronic effects of sulindac on renal function in chronic renal disease. Clin Pharmacol Ther 37:298-300, 1985
164. Klassen DK, Stout RL, Spilman PS, Whelton A: Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. J Clin Pharmacol 29:1037-1042, 1989
165. Ravis WR, Diskin CJ, Campagna KD, Clark CR, McMillian CL: Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J Clin Pharmacol 33:527-534, 1993
166. Gibson TP, Dobrinska MR, Lin JH, Entwistle LA, Davies RO: Biotransformation of sulindac in end-stage renal disease. Clin Pharmacol Ther 42:82-88, 1987
167. Brater DC, Lasseter KC: Profile of etodolac: pharmacokinetic evaluation in special populations. Clin Rheumatol 8(Suppl 1):25-35, 1989
168. Ermer JC, Boni JP, Cevallos WH, DeCleene S, Burghart P, Rudnick MR, Fruncillo RJ, Berns JS, Cohen RM: Bromfenac disposition in patients with impaired kidney function. Clin Pharmacol Ther 61:312-318, 1997
169. Skoutakis VA, Acchiardo SR, Carter CA, Wojciechowski NJ, Straughn AB, Meyer MC: Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. Drug Intell Clin Pharm 20:956-960, 1986
170. Taylor IW, Taylor T, James I, Doyle G, Dorf G, Darragh A, Chasseaud LF: Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy subjects and in disease states. Eur J Clin Pharmacol 40:101-106, 1991
171. Aronoff GR, Ozawa T, DeSante KA, Nash JF, Ridolfo AS: Benoxaprofen kinetics in renal impairment. Clin Pharmacol Ther 32:190-194, 1982
172. Stafanger G, Larsen HW, Hansen H, Sorensen K: Pharmacokinetics of ketoprofen in patients with chronic renal failure. Scand J Rheumatol 10:189-192, 1981
173. Taylor IW, Chasseaud LF, Taylor T, James I, Dorf G, Darragh A: Pharmacokinetics of the anti-inflammatory drug ximoprofen in healthy young and elderly subjects: comparison with elderly rheumatic patients. Br J Clin Pharmacol 32:242-245, 1991
174. Anttila M, Haataja M, Kasanen A: Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol 18:263-268, 1980
175. Rogers HJ, Savitsky JP, Glenn B, Spector RG: Kinetics of single doses of fenbufen in patients with renal insufficiency. Clin Pharmacol Ther 29:74-80, 1981
176. Grubb NG, Rudy DW, Brater DC, Hall SD: Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. Br J Clin Pharmacol 48:494-500, 1999
177. Cefali EA, Poynor WJ, Sica D, Cox S: Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. J Clin Pharmacol 31:808-814, 1991
178. al-Ghamdi MS, al-Mohanna FA, al-Mustafa ZH, al-Saeed IS: The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. Eur J Clin Pharmacol 43:197-199, 1992
179. Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38:225-242, 2000
180. Gottesdiener K, Agrawal N, Porras A, Wong P, Rogers JD, Gertz BJ, Redfern JS, Marbury T: Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. Am J Ther 10:252-258, 2003
181. Udayaraj UP, Steenkamp R, Caskey FJ, Rogers C, Nitsch D, Ansell D, Tomson CR: Blood pressure and mortality risk on peritoneal dialysis. Am J Kidney Dis 53:70-78, 2009